News

PRIMARY ENDPOINT FOR DEXTENZA NOT ACHIEVED Ocular Therapeutix announced topline results from its second phase 3 clinical trial to evaluate the safety and efficacy of Dextenza (sustained-release dexamethasone) Intracana...